This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
== Pregnancy == About 50% of women experience low back pain during pregnancy. Some studies have suggested that women who have experienced back pain before pregnancy are at a higher risk of experiencing back pain during pregnancy. It may be severe enough to cause significant pain and disability in as many as one third of pregnant women. Back pain typically begins at approximately 18 weeks of gestation and peaks between 24 and 36 weeks. Approximately 16% of women who experience back pain during pregnancy report continued back pain years after pregnancy, indicating that those with significant back pain are at greater risk of back pain following pregnancy. Biomechanical factors of pregnancy shown to be associated with back pain include increased curvature of the lower back, or lumbar lordosis, to support the added weight on the abdomen. Also, the hormone relaxin is released during pregnancy, which softens the structural tissues in the pelvis and lower back to prepare for vaginal delivery. This softening and increased flexibility of the ligaments and joints in the lower back can result in pain. Back pain in pregnancy is often accompanied by radicular symptoms, suggested to be caused by the baby pressing on the sacral plexus and lumbar plexus in the pelvis. Typical factors aggravating the back pain of pregnancy include standing, sitting, forward bending, lifting and walking.
== N == Nametkin rearrangement Narasaka–Prasad reduction Nazarov cyclization reaction Neber rearrangement Nef reaction Negishi coupling Negishi zipper reaction Nenitzescu indole synthesis Nenitzescu reductive acylation Newman–Kwart rearrangement Nicholas reaction Niementowski quinazoline synthesis Niementowski quinoline synthesis Nierenstein reaction NIH shift Ninhydrin test Nitroaldol reaction Nitrone-olefin 3+2 cycloaddition Normant reagents Noyori asymmetric hydrogenation Nozaki–Hiyama–Kishi reaction Nucleophilic acyl substitution
Epidermolysis bullosa acquisita, also known as acquired epidermolysis bullosa, is a longterm autoimmune blistering skin disease. It generally presents with fragile skin that blisters and becomes red with or without trauma. Marked scarring is left with thin skin, milia and nail changes. It typically begins around age 50. It is caused by antibodies to type VII collagen within anchoring fibril structures located at the dermoepidermal junction in skin. Damaged skin may become infected. Diagnosis is by observing the persistence of the condition, direct immunofluorescence, and detecting autoantibodies against type VII collagen. It can appear similar to porphyria cutanea tarda, pemphigoid, pemphigus, dermatitis herpetiformis, or blistering drug eruption. The condition is longterm and has no cure. A good response may be seen with corticosteroids, either alone or combined with azathioprine or dapsone. It is rare, with around 0.08 to 0.5 new cases per million people per year, and it affects males and females equally.
CoviVac – COVID vaccine Cytestrol acetate – antiestrogen, cytostatic antineoplastic agent Deltaran (delta sleep-inducing peptide) – alcohol withdrawal treatment Dilept (GZR-123) – antipsychotic, neurotensin analogue Diucifon – leprostatic agent Emoxypine (Mexidol; Mexifin) – actoprotector, antioxidant EpiVacCorona – COVID vaccine Eprobemide (Befol) – antidepressant, reversible inhibitor of monoamine oxidase A Ethacizine (ethacyzine; Ethacizin) – antiarrhythmic agent Fabomotizole (Afobazole) – anxiolytic Feprosidnine (Sydnophen) – amphetamine derivative, psychostimulant Fluacizine (Phtorazisin) – tricyclic antidepressant, phenothiazine Fluorothiazinone (CL-55; Ftortiazinon) – investigational antibiotic Fotretamine (Fotrin) – alkylating antineoplastic agent, immunosuppressant Gamofen (gamophen; amphetamine–GABA) – amphetamine derivative, GABATooltip γ-aminobutyric acid analogue, central agent, central depressant Gidazepam (hydazepam, hidazepam) – atypical benzodiazepine, anxiolytic, TSPOTooltip translocator protein agonist/ligand Gludantan (gludantane) – adamantane, antiparkinsonian agent, antidepressant Glufimet (RGPU-238; dimethyl 3-phenylglutamate) – GABATooltip γ-aminobutyric acid and phenibut analogue Glutaron (RGPU-135; neuroglutamine, neuroglutam; β-phenylglutamate; 3-phenylglutamate) – glutamate analogue, psychostimulant, antidepressant, anxiolytic, neuroprotective Hemantane (hymantane) – adamantane, antiparkinsonian agent Hopantenic acid (homopantothenic acid; N-pantoyl-GABA; Pantogam) – central depressant, GABATooltip γ-aminobutyric acid analogue Ipidacrine (Neiromidin) – acetylcholinesterase inhibitor Latrepirdine (dimebolin; Dimebon) – antihistamine, antiserotonergic, nootropic Mecigestone (pentarane B) – progestin Megestrol caproate (MGC) – progestin Meldonium (Mildronate) – anti-ischemia agent Menthyl isovalerate (validolum; Extravalerianic, Validol, Valofin, Menthoval) – anxiolytic Mesocarb (Sidnocarb, Sydnocarb, Synocarb) – amphetamine derivative, psychostimulant Methylphenatine – amphetamine derivative, psychostimulant Methylphenylpiracetam – racetam, sigma σ1 receptor positive allosteric modulator α-Methyltryptamine (αMT; Indopan) – tryptamine derivative, antidepressant Metralindole (Inkazan) – antidepressant, reversible inhibitor of monoamine oxidase A Moracizine (moricizine; Ethmozine) – antiarrhythmic agent Nooglutyl (Nooglutil; N-5-hydroxynicotinoyl-L-glutamate) – nootropic Orenetide (BP101; Libicore; Desirix; Thr-Lys-Pro-Arg-Pro) – investigational small peptide, sexual enhancer Pabofen (pabophen; amphetamine–PABA) – amphetamine derivative, antihypoxic agent Pentarane A (D'6-pentarane) – progestin Phemerazole (femerazol; 5-phenyl-3-methylpyrazole) – sedative, hypnotic, anticonvulsant, muscle relaxant, mammary stimulant Phenatine (phenatin; Fenatine; amphetamine–niacin; N-nicotinoylamphetamine) – amphetamine derivative, psychostimulant, hypotensive agent Phenazepam – benzodiazepine, anxiolytic, sedative, hypnotic Phenibut (β-phenyl-GABA; Anvifen, Fenibut, Noofen; Citrocard, RGPU-147) – central depressant, anxiolytic, GABATooltip γ-aminobutyric acid analogue, gabapentinoid N-Phenylacetyl-L-prolylglycine ethyl ester (omberacetam; Noopept) – nootropic, racetam, cyclic glycine-proline prodrug Phenylphenamine (phenylamphetamine) – amphetamine derivative Phenylpiracetam (fonturacetam; Phenotropil, Actitropil, Carphedon) – psychostimulant, nootropic, racetam Phenylpiracetam hydrazide (fonturacetam hydrazide) – anticonvulsant, racetam Picamilon (N-nicotinoyl-GABA, pycamilon, and pikamilon) – anxiolytic, GABATooltip γ-aminobutyric acid analogue Pipofezine (Azafen, Azaphen) – tricyclic antidepressant Pirlindole (Lifril, Pyrazidol) – antidepressant, reversible inhibitor of monoamine oxidase A, serotonin–norepinephrine reuptake inhibitor Polymethylsiloxane polyhydrate (PMSPH; methylsilicic acid hydrogel; Enterosgel) – enterosorbent Propylphenamine (propylamphetamine; possibly N-propylamphetamine) – amphetamine derivative Prospidium chloride (prospidine) – cytostatic, anti-inflammatory agent Pyridoxiphen (amphetamine–pyridoxine; pyridoxylamphetamine) – amphetamine derivative, sympatholytic, hypotensive agent Quifenadine (Phencarol, Fencarol) – antihistamine RGPU-95 (p-chlorophenylpiracetam) – antidepressant, anxiolytic, racetam RGPU-207 (cyclic GABA derivative) – GABATooltip γ-aminobutyric acid analogue, mitochondrial modulator, racetam RGPU-260 – GABATooltip γ-aminobutyric acid analogue, cardiac stimulant Riamilovir (Triazavirin) – antiviral RU-1205 – analgesic, kappa opioid receptor agonist Selank – tuftsin analogue, nootropic, anxiolytic Semax – ACTHTooltip adrenocorticotropic hormone fragment analogue, nootropic, neuroprotective, neurorestorative Sodium polydihydroxyphenylene thiosulfonate (Hypoxen) – antihypoxic agent Sputnik Light – COVID vaccine Sputnik V – COVID vaccine Sulfozinum (sulfazin) – pyrogenic and pain-inducing agent used in psychiatry, for instance psychosis Temgicoluril (tetramethylglycoluril; Adaptol, Mebicar, Mebicarum, Mebikar) – anxiolytic Testifenon (testiphenon, testiphenone, chlorphenacyl dihydrotestosterone ester) – androgen/anabolic steroid, cytostatic antineoplastic agent Tetrindole – antidepressant, reversible inhibitor of monoamine oxidase A Thiophenatine (N-thionicotinoylamphetamine) – amphetamine derivative Tipindole – serotonin antagonist and monoamine oxidase inhibitor Tolibut (β-(4-methylphenyl)-GABA)) – anxiolytic, analgesic, neuroprotective, GABATooltip γ-aminobutyric acid and phenibut analogue Traneurocin (cycloprolylglycine; CPG; NA-831) – racetam-like neuroprotective, neurogenic, nootropic, and anxiolytic Trimeperidine – opioid analgesic Umifenovir (Arbidol) – antiviral Vishnevsky liniment – topical wound medication Phenamine (Fenamin), a psychostimulant, is not specifically a Russian drug but is rather the Russian name for amphetamine.
The Welsh Conservatives are absent from a Senedd debate concerning their former leader, Andrew RT Davies, but reject allegations they are boycotting the chamber's disciplinary process. 6 February – Chris McEleny is suspended as general secretary of the Alba Party following allegations of gross misconduct. 7 February – Reform UK chairman Zia Yusuf tells the BBC's Political Thinking podcast that history will judge Boris Johnson as one of the most damaging prime ministers in British history. 8 February – Health Minister Andrew Gwynne is sacked by the prime minister after the Mail on Sunday reported he sent a string of abusive and insulting WhatsApp about constituents and colleagues. Gwynne apologises for what he describes as the "badly misjudged" messages. 9 February – Conservative shadow minister Alex Burghart tells the BBC's Sunday with Laura Kuenssberg there is "not a conversation to be had" about suggestions of an electoral pact with Reform UK. Oliver Ryan, MP for Burnley, becomes the second MP to apologise for inappropriate comments made in a WhatsApp chat. 10 February – Peter Mandelson begins his tenure as United Kingdom ambassador to the United States, and tells the BBC the UK must respect President Donald Trump's "strong and clear mandate for change". Oliver Ryan is suspended from the Parliamentary Labour Party over his membership of a WhatsApp group in which offensive messages were exchanged. King Charles III gives the prime minister and deputy prime minister a tour of his environmentally friendly, sustainable housing project at Nansledan in Cornwall.
Sources: en.wikipedia.org
== Grading == The severity of cirrhosis is commonly classified with the Child–Pugh score (also known as the Child–Pugh–Turcotte score). This system was devised in 1964 by Child and Turcotte, and modified in 1973 by Pugh and others. It was first established to determine who would benefit from elective surgery for portal decompression. This scoring system uses multiple lab values including bilirubin, albumin, and INR. The presence of ascites and severity of encephalopathy is also included in the scoring. The classification system includes class A, B, or C. Class A has a favorable prognosis while class C is at high risk of death.
== History == Avobenzone was patented in 1973 and was approved in the EU in 1978. It was approved by the FDA in 1988. As of 2021, the FDA announced that they do not support avobenzone as being generally recognized as safe and effective (GRASE) citing the need for additional safety data. Avobenzone was banned in 2020 by the Palau government citing reef-toxicity concerns.
==== Nasal inhalation ==== Inhalation by nose of a substance is almost identical to oral inhalation, except that some of the drug is absorbed intranasally instead of in the oral cavity before entering the airways. Both methods can result in varying levels of the substance to be deposited in their respective initial cavities, and the level of mucus in either of these cavities will reflect the amount of substance swallowed. The rate of inhalation will usually determine the amount of the substance which enters the lungs. Faster inhalation results in more rapid absorption because more substance finds the lungs. Substances in a form that resists absorption in the lung will likely resist absorption in the nasal passage, and the oral cavity, and are often even more resistant to absorption after they fail absorption in the former cavities and are swallowed.
== The genome of Elusimicrobium minutum == The 1.64 Mbp genome of E. minutum reveals the presences of several genes required for uptake and fermentation of sugars via the Embden–Meyerhof pathway, including several hydrogenases, and an unusual peptide degradation pathway comprising transamination reactions. It also reveals the presence of genes coding for peptidoglycan and lipopolysaccharide biosynthesis. The genome also seems to encode 60 PilE genes putatively involved in pilus assembly, polyketide synthesis, non-ribosomal peptide synthesis and many other still undiscovered metabolic traits.
Etifoxine is used pharmaceutically as the hydrochloride salt. (S)-Etifoxine, the (S) enantiomer of etifoxine, was under development by Anvyl Pharmaceuticals for the treatment of neuropathic pain, but development was discontinued. A deuterated form of etifoxine with improved pharmacokinetics known as deuterated etifoxine (GRX-917) is under development by GABA Therapeutics for the treatment anxiety and mood disorders.
Sources: en.wikipedia.org
Indeed, the AAS mesterolone has been used to improve sperm quality and fertility in men because, apparently unlike other AAS, it shows minimal antigonadotropic effects at typical clinical dosages but activates the AR and thereby supports sperm maturation in the epididymides. However, this use of mesterolone is controversial and its efficacy for such purposes is not fully certain. Although bicalutamide alone would appear to have minimal detrimental effect on testicular spermatogenesis and hence on certain aspects of male fertility, other hormonal agents that bicalutamide may be combined with, including GnRH analogues and particularly estrogens (as in transgender hormone therapy), can have a considerable detrimental effect on fertility. This is largely a consequence of their antigonadotropic activity. Antigonadotropic agents like high-dose CPA, high-dose androgens (e.g., testosterone esters), and GnRH antagonists (though notably not GnRH agonists in the case of fertility) produce hypogonadism and high rates of severe or complete infertility (e.g., severe oligospermia or complete azoospermia) in men. However, these effects are fully and often rapidly reversible with their discontinuation, even after prolonged treatment. In contrast, while estrogens at sufficiently high dosages similarly are able to produce hypogonadism and to abolish or severely impair spermatogenesis, this is not necessarily reversible in the case of estrogens and can be long-lasting after prolonged exposure.
=== Polyendocrine metabolic ovarian syndrome === Inositol is considered a safe and effective treatment for polyendocrine metabolic ovarian syndrome (PMOS), formerly referred to as polycystic ovary syndrome (PCOS). The following clinical outcomes of myo-inositol therapy for patients with PMOS have been observed:
In some instances 189F can combine with a helium nucleus, forming 2111Na, to start a neon-sodium cycle, in which: 2111Na → 2110Ne → 2211Na → 2210Ne → 2311Na → 2010Ne → 2111Na The sodium-23 can also turn into magnesium-24 after proton bombardment, initiating a magnesium-aluminium cycle, in which: 2412Mg → 2513Al → 2512Mg → 2613Al → 2612Mg → 2713Al → 2412Mg
== Chemistry == PSK is a protein polysaccharide consisting of a beta-glucan β-1,4 main chain with β-1,3 and β-1,6 side chains. The approximate molecular weight of PSK is 100,000 Da, and the protein component is reported at the β-1,6 side chain. PSK is isolated from the "CM-101" strain of Trametes versicolor. The analogous compound PSP, is derived from the "COV-1" strain of Trametes versicolor.
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.